KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Bristol Myers Squibb (BMY) R&D In Process (2021 - 2025)

Bristol Myers Squibb (BMY) has disclosed R&D In Process for 5 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, R&D In Process rose 4540.0% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 billion, a 72.18% decrease, with the full-year FY2025 number at $3.7 billion, down 72.18% from a year prior.
  • R&D In Process was $1.4 billion for Q4 2025 at Bristol Myers Squibb, up from $633.0 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $12.9 billion in Q1 2024 to a low of $6.0 million in Q1 2021.
  • A 5-year average of $999.0 million and a median of $225.0 million in 2024 define the central range for R&D In Process.
  • Peak YoY movement for R&D In Process: soared 17165.33% in 2024, then crashed 98.55% in 2025.
  • Bristol Myers Squibb's R&D In Process stood at $89.0 million in 2021, then plummeted by 41.57% to $52.0 million in 2022, then surged by 1053.85% to $600.0 million in 2023, then tumbled by 95.0% to $30.0 million in 2024, then skyrocketed by 4540.0% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's R&D In Process are $1.4 billion (Q4 2025), $633.0 million (Q3 2025), and $1.5 billion (Q2 2025).